What The White House Is NOT Telling You About The "Green Revolution."
Governments across the globe want to go "All Electric" by 2035. There's one rare metal that could cripple these plans. Without it, going green is impossible. And that's why there's a modern-day gold-rush for this rare metal.
Read The Full Story On This "Gold Rush"

SONN Insider Trading (Sonnet BioTherapeutics)

Insider Ownership Percentage: 6.90%
Insider Buying (Last 12 Months): $88,200.00
Insider Selling (Last 12 Months): $0.00

Sonnet BioTherapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Sonnet BioTherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sonnet BioTherapeutics Share Price & Price History

Current Price: $0.63
Price Change: Price Decrease of -0.02 (-3.06%)
As of 10/19/2021 01:00 AM ET

This chart shows the closing price history over time for SONN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
What The White House Is NOT Telling You About The "Green Revolution."
Governments across the globe want to go "All Electric" by 2035. There's one rare metal that could cripple these plans. Without it, going green is impossible. And that's why there's a modern-day gold-rush for this rare metal.
Read The Full Story On This "Gold Rush"

Sonnet BioTherapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/9/2021Pankaj MohanCEOBuy32,000$1.55$49,600.00View SEC Filing Icon  
6/9/2021Richard T. KenneyInsiderBuy15,000$1.54$23,100.00View SEC Filing Icon  
5/19/2021Richard T. KenneyInsiderBuy10,000$1.55$15,500.00View SEC Filing Icon  
6/11/2020Albert D DyrnessDirectorBuy2,409$3.79$9,130.11
See Full Table
Insider Selling at Sonnet BioTherapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Sonnet BioTherapeutics and related companies.

SEC Filings (Institutional Ownership Changes) for Sonnet BioTherapeutics (NASDAQ:SONN)

4.50% of Sonnet BioTherapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SONN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Sonnet BioTherapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/16/2021State Street Corp62,688$99K0.0%N/A0.253%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.701,634$1.11M0.0%+416.0%2.834%Search for SEC Filing on Google Icon
5/19/2021Virtu Financial LLC65,106$0.15M0.0%N/A0.371%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC113,264$0.26M0.0%N/A0.534%Search for SEC Filing on Google Icon
5/18/2021Jane Street Group LLC17,304$39K0.0%N/A0.099%Search for SEC Filing on Google Icon
5/17/2021Price T Rowe Associates Inc. MD45,100$0.10M0.0%N/A0.257%Search for SEC Filing on Google Icon
5/13/2021Bank of New York Mellon Corp20,399$46K0.0%N/A0.116%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.255,761$0.58M0.0%+3.7%1.457%Search for SEC Filing on Google Icon
3/26/2021Susquehanna International Group LLP15,434$34K0.0%N/A0.088%Search for SEC Filing on Google Icon
2/9/2021Advisory Services Network LLC24,581$55K0.0%+32.3%0.143%Search for SEC Filing on Google Icon
2/5/2021BlackRock Inc.246,555$0.55M0.0%+2.5%1.435%Search for SEC Filing on Google Icon
11/19/2020Schonfeld Strategic Advisors LLC12,200$31K0.0%N/A0.071%Search for SEC Filing on Google Icon
11/19/2020IHT Wealth Management LLC10,000$26K0.0%N/A0.058%Search for SEC Filing on Google Icon
11/17/2020Schonfeld Strategic Advisors LLC12,200$31K0.0%N/A0.089%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Sonnet BioTherapeutics logo
Sonnet BioTherapeutics Holdings, Inc., an oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding (FHAB) technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate includes SON-080, a human version of low dose Interleukin-6 (IL-6), which has completed Phase I trials for the treatment of patients with chemotherapy-induced peripheral neuropathy. The company is also developing SON-081, a low dose IL-6 for the treatment of patients with diabetic peripheral neuropathy and is under phase I trials; SON-1010, a FHAB derived compound, which utilizes a human version of Interleukin-12 (IL-12) is under pre-clinical trial, as well as SON-1210, a bi-specific construct that combines FHAB with IL-12 and human Interleukin-15 for the treatment of solid tumor is under pre-clinical trial. In addition, it develops SON-2014, a bi-specific combination of granulocyte-macrophage colony stimulating factor and Interleukin-18 for the treatment of cancer; and SON-3015, a bi-specific combination of anti-IL6 and anti-tumor growth factor beta for tumor and bone metastases. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
Read More on Sonnet BioTherapeutics

Today's Range

Now: $0.63
Low: $0.62
High: $0.65

50 Day Range

MA: $0.68
Low: $0.56
High: $1.22

52 Week Range

Now: $0.63
Low: $0.55
High: $3.42

Volume

2,478,029 shs

Average Volume

4,178,310 shs

Market Capitalization

$15.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Who are the company insiders with the largest holdings of Sonnet BioTherapeutics?

Sonnet BioTherapeutics' top insider investors include:
  1. Albert D Dyrness (Director)
  2. Pankaj Mohan (CEO)
  3. Richard T Kenney (Insider)
What The White House Is NOT Telling You About The "Green Revolution."
Governments across the globe want to go "All Electric" by 2035. There's one rare metal that could cripple these plans. Without it, going green is impossible. And that's why there's a modern-day gold-rush for this rare metal.
Read The Full Story On This "Gold Rush"